UCB announces new EULAR 2026 data show CIMZIA (certolizumab pegol) delivered consistent effect in rheumatoid arthritis, regardless of rheumatoid factor (RF) levels (€259.50, 0.00)
Transcript Intelligence: Astellas Pharma at Jefferies Global Healthcare Conference
Pfizer announces TALZENNA plus XTANDI improves radiographic progression-free survival by more than 50% in metastatic prostate cancer ($26.18, 0.00)
StreetAccount Summary - Trading higher/lower: Japan mid-day
Astellas Pharma formulates corporate strategic plan; aims to achieve ¥4.3T in core operating profit (¥2233.5000, 0)
StreetAccount Sector Summary - Healthcare Pre-Market
EU's CHMP adopted a positive opinion recommending a change to the terms of the marketing authorisation for Padcev (¥2269.5000, 0)
EMA CHMP publishes summary of opinions for May 2026 meeting
Merck receives positive EU CHMP opinion for KEYTRUDA (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv) as perioperative treatment for adults with cisplatin-ineligible Resectable muscle-invasive bladder cancer ($115.88, 0.00)
Astellas Pharma announces results from post hoc analysis of GATHER1 and GATHER2 pivotal studies of IZERVAY (¥2328.0000, 0)
Powered by FactSet Research Systems Inc.